All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Selina M. Luger, University of Pennsylvania, Philadelphia, US. We asked: What are the current challenges in ALL that need to be addressed?
What are the current challenges in ALL that need to be addressed?
Here, she highlights a number of considerations regarding ALL treatment strategies:
1) Should all patients receive transplant for the treatment of ALL?
2) Do all patients with Philadelphia chromosome-positive ALL require intensive chemotherapy?
3) Are there patients with Philadelphia chromosome-negative ALL who demonstrate good responses without chemotherapy?
4) Should targeted agents be incorporated into chemotherapy regimens?
Selina M. Luger concludes by highlighting the lack of targeted agents available for T-cell ALL and outlines emerging therapeutics in this setting.
Comparison of toxicities in young adults with ALL in CALGB 10403 and COG AALL0232
Superior outcomes have been reported in retrospective studies of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL) compared with...
Phase I results show venetoclax and navitoclax combination is tolerable and associated with responses in pediatric patients with R/R ALL and LL
The prognosis is poor for pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leukemia...
Subscribe to get the best content related to ALL delivered to your inbox